Royalty Pharma Surges to 413th in Daily Rankings with $384 Million Turnover Amid FDA Decision Anticipation

On May 30, 2025, Royalty Pharma (RPRX) saw a significant surge in trading volume, with a total turnover of $384 million, marking a 395.25% increase from the previous day. This substantial rise in trading activity placed Royalty Pharma at the 413th position in the daily stock market rankings. The stock price of Royalty Pharma increased by 0.74%, marking the second consecutive day of gains, with a total increase of 0.77% over the past two days.

Royalty Pharma is eagerly awaiting a pivotal FDA decision on September 26, 2025, regarding Aficamten, a drug designed to treat obstructive hypertrophic cardiomyopathy. This decision holds significant market potential, with analysts predicting blockbuster status for the drug. The outcome of this FDA decision is crucial for Royalty Pharma, as it could greatly impact the company's future prospects and stock performance.

In the competitive landscape, Bristol-Myers Squibb’s Camzyos is a notable rival drug. The market's anticipation of Aficamten's approval reflects the high stakes involved in this FDA decision. Investors are closely monitoring the situation, as a positive outcome could drive Royalty Pharma's stock price higher, while a negative decision could lead to a decline.